2076975 2077203
최종편집 2020-12-04 02:25 (금)
Korea’s exports of high-ranked pharmaceutical companies on recovery path in 3Q.
상태바
Korea’s exports of high-ranked pharmaceutical companies on recovery path in 3Q.
  • Hyeokgi Lee, Newsmp
  • 승인 2020.11.11 16:59
  • 댓글 0
이 기사를 공유합니다

    Green Cross over KRW 50 billion (USD 44.9 million) for two consecutive quarters… Hanmi     Pharmaceutical remains KRW 40 billion (USD 35.9 million) 
Yuhan Corp.ㆍDong-A ST back to KRW 40 billion (USD 35.9 million)… Daewoong Pharma to KRW 10 billion (USD 8.9 million)


Top pharmaceutical companies, which struggled in the first half last year in the aftermath of the COVID-19 pandemic, almost recovered their export performance in 3Q to previous year’s, the report showed. 

According to Newsmp, the combined exports of five high-ranked pharmaceutical companies in 3Q was KRW 189.4 billion (USD 170 million), close to KRW 191 billion (USD 171.7 million) of last year.

▲ Top pharmaceutical companies, which struggled in the first half last year in the aftermath of the COVID-19 pandemic, almost recovered their export performance in 3Q to previous year’s, the report showed. 
▲ Top pharmaceutical companies, which struggled in the first half last year in the aftermath of the COVID-19 pandemic, almost recovered their export performance in 3Q to previous year’s, the report showed. 

Green Cross’ exports of 3Q reached KRW 52.1 billion (USD 46.85 million), a 26.2% increase over the same quarter last year, exceeding KRW 50 billion (USD 44.9 million) for two consecutive quarters.

Hanmi Pharmaceutical also maintained KRW 40 billion (USD 35.9 million) level for two quarters in a row with exports of KRW 41.6 billion (USD 37.4 million), up 6.1% from the same period last year.

Yuhan Corp., which recorded over KRW 40 billion (USD 35.9 million) exports in all four quarters last year, had stayed around KRW 20 billion (USD 17.98 million) in 1Q and 2Q, but finally escaped from negative growth with KRW 40 billion (USD 35.9 million) in 3Q.   

Dong-A ST has not yet recovered to the same level (KRW 45.8 billion, USD 41.19 million) of 3Q of last year, but returned to KRW 40 billion (USD 35.9 billion) from KRW 30 billion (USD 26.97 million), and Daewoong Pharmaceutical, under KRW 10 billion in 2Q, exceeded KRW 10 billion (USD 8.9 million) in 3Q.

The exports ratio to the average sales of the five companies in the 3Q was 12.54%, still 0.89%p lower than the same period last year, but the gap narrowed to within 1%p.

However, exports ratio to 9-month sales was 13.10%, 2%p lower than 3Q last year, which exceeded 15%.

By company, the ratio of Green Cross exports to sales in 3Q was 12.42%, up 1.25%p from a year ago, while Hanmi Pharmaceutical gained 0.84%p to 15.59%.

On the contrary, Daewoong Pharmaceutical plunged 4.31%p to 4.10%, and Yuhan Corp. recovered 10.45%, but still 1.14%p lower than the same period last year. 

Dong-A ST had the highest exports ratio to sales among five pharmaceutical companies with 27.88% but was 0.44%p less than the same quarter a year ago. 
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.